T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

• Arjan Diepstra,
• Lydia Visser,
• Catherine Fortpied,
• Walter Noordzij,
• Annika Loft,
• Anne Arens,
• Anna Sureda-Balari,
• Susana Carvalho,
• Andrej Vranovský,
• Ward Sents,
• Emanuel Buhrer,
• Wouter J. Plattel,
• Martin Hutchings

Affiliations

Arjan Diepstra

1 Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands

Lydia Visser

1 Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands

Catherine Fortpied

2 EORTC Headquarters, Brussels, Belgium

Walter Noordzij

3 Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, the Netherlands

Annika Loft

4 Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital, Denmark

Anne Arens

5 Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

Anna Sureda-Balari

6 Institut Català d’Oncologia-Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, Universitat de Barcelona, Barcelona, Spain 6Instituto Português de Oncologia de Lisboa, Lisbon, Portugal

Susana Carvalho

7 Instituto Portoguês de Oncologia de Lisboa, Lisbon, Portugal

Andrej Vranovský

8 Department of Oncohematology, Comenius University in Bratislava and National Cancer Institute, Bratislava, Slovakia

Ward Sents

2 EORTC Headquarters, Brussels, Belgium

Emanuel Buhrer

2 EORTC Headquarters, Brussels, Belgium

Wouter J. Plattel

9 Department of Haematology, University of Groningen, University Medical Center Groningen, the Netherlands

Martin Hutchings

10 Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Denmark